ClinicalTrials.gov
public full text
Public Domain
Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injuries Behavior Associated With Prader-Willi Syndrome
This is a placebo-controlled clinical trial to assess the utility of Guanfacine Extended Release (GXR) in the management of patients with Prader Willi Syndrome (PWS) who have significant aggression or self-injury. The purpose of this trial is to establish the safety of GXR with a specific focus on metabolic effects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Guanfacine in Children With Tic Disorders#812806
- Implementation of a HABIT-ILE Intervention at William Lennox Neurological Hospital (NeuREHA)#887955
- Efficacy and safety of gepants in migraine management: a narrative review focusing on atogepant and rimegepant#1000632
- A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine#980559
- GDNF in ideopathicParkinsons Disease#844651
Record · ID 1173015
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive